Sana Biotechnology
Facts
- HQ
- Washington state
- Sectors
- Biotechnology, Gene editing
- Founded
- 2018 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Sana Biotechnology Inc Seattle business license
- Stage
- Public
Notch Therapeutics raises $85M Series A (total $91M) to fund stem cell–derived T cell therapies and open Seattle lab
Notch Therapeutics raised an $85 million Series A, bringing total funding to $91 million, to advance stem cell–derived T cell immunotherapies and expand with a new Seattle research lab. The 2018-founded biotech plans to grow from 35 to about 100 employees by end of 2022 and is collaborating with Allogene Therapeutics on treatments for blood cancers.
Nautilus Biotechnology to go public via Arya Sciences Acquisition Corp III SPAC, raising $350M at $900M valuation
Nautilus Biotechnology, a Seattle proteomics startup led by Sujal Patel and Parag Mallick, will go public via a SPAC merger with Arya Sciences Acquisition Corp III, raising about $350 million and valuing the company at $900 million. The deal includes a $150 million SPAC component and a $200 million PIPE, expects to close in Q2, and the combined company will trade on Nasdaq as NAUT.
Sana Biotechnology Raises $587.5M in IPO, Debuts on Nasdaq as SANA with $6B Market Value
Sana Biotechnology raised $587.5 million by pricing 23.5 million shares at $25 in its IPO and began trading on Nasdaq under ticker SANA, with shares jumping about 40% on debut to close at $35.10. The 3-year-old Seattle gene-editing company, pre-revenue and led by former Juno executives, aims to use the proceeds to advance gene and cell therapies—including cancer treatments—and may file drug applications as early as 2022.
Sana Biotechnology ups IPO to 22M shares at $23–$24, targeting ~$517M at midpoint after $700M+ VC funding
Sana Biotechnology raised its IPO target to 22 million shares at $23–$24 each, expecting about $517 million at the midpoint, after previously aiming much lower and following over $700 million in venture funding. The Seattle gene- and cell-therapy startup plans near-term cancer treatments and broader goals to modify any gene or replace damaged cells.
PitchBook: Silicon Valley VC Deal Share to Drop Below 20% This Year as Investors Move to Miami, Austin and Other Hubs
PitchBook forecasts that Silicon Valley’s share of U.S. venture capital deal count will fall below 20% this year for the first time, as remote work, high local costs and investor relocations shift capital to secondary tech hubs. In 2020 the U.S. raised $156.2 billion in VC, with the Bay Area accounting for 22.7% of deals and 39.4% of deal value.
Sana Biotechnology files IPO to raise up to $150M, aims to trade as SANA while advancing in‑body gene and cell therapies
Sana Biotechnology, founded less than three years ago with no revenue, filed to go public on Nasdaq under ticker SANA seeking to raise up to $150 million while developing gene and cell therapies aimed at controlling or modifying genes and treating cancers. The Seattle-area startup has raised over $700 million in venture funding, held $459 million in cash and equivalents at September-end, but carries a $316 million accumulated deficit.
Seattle Reaches 10 Unicorns Worth $1B+, Mostly Enterprise Software Firms with Microsoft Links
Seattle now has 10 unicorn startups valued at $1 billion or more, many concentrated in enterprise software/cloud computing and driven by rapid digital transformation and strong revenue run rates. Most have immigrant founders and Microsoft ties, but none have female co-founders or CEOs.
Umoja Biopharma raises $53M Series A to develop in vivo CAR T-cell immunotherapies for adult and pediatric tumors
Seattle-based Umoja Biopharma raised $53 million in a Series A to advance its preclinical in vivo CAR T-cell immunotherapy platform for blood and organ tumors in adult and pediatric patients, aiming to generate cancer-fighting cells inside the body. The company was founded last year by CEO Andy Scharenberg and collaborators from Seattle Children’s Research Institute and Purdue University, with MPM Capital and Qiming Venture Partners USA leading the round.
Sana CEO Steve Harr Details Cell- and Gene-Therapy Plans After $700M+ Summer Raise
Sana Biotechnology CEO Steve Harr described the stealthy, Seattle-based gene and cell therapy startup’s plan to develop tools that repair and replace human cells to treat diseases and create new medicines, after raising more than $700 million this summer. Founded in 2019 by former Juno Therapeutics executives, the 250-person company emphasizes faster decision-making, focus, and communication as its competitive edge against larger rivals.
98point6 Raises $118M Series E Led by L Catterton and Activant After 274% Membership Surge
Seattle telemedicine startup 98point6 raised $118 million in a Series E led by L Catterton and Activant Capital after membership grew 274% this year; the company offers AI-supported virtual primary care to over 3 million patients and serves employers and health plans. The round follows a $43 million Series D in April and comes amid a surge in digital health funding during the pandemic.
GeekWire Awards 2020 Goes Virtual; Ally Wins Startup of the Year as Bill Gates and Celebrities Celebrate
GeekWire held a virtual GeekWire Awards livestream honoring top Pacific Northwest tech companies and leaders across 12 categories, with winners accepting via Zoom and special video messages from figures like Bill Gates. Seattle startup Ally won Startup of the Year, and the event included entertainment such as The Drunken Tenorperforming an "Opera di Zoom."
Pacific Northwest startups attract $2.3B in H1 2020 as Sana Biotech’s >$700M June raise boosts totals
Despite the pandemic and recession fears, Pacific Northwest startups attracted $2.3 billion across 135 deals in H1 2020, up from $1.1 billion in 94 deals in H1 2019; Seattle-based Sana Biotechnology’s >$700 million June raise heavily skewed totals but H1 2020 still topped $1.6 billion excluding that deal.
Sana Biotechnology raises over $700M (SEC filings suggest $866.8M total) to advance gene and cell therapies
Sana Biotechnology announced it has raised more than $700 million in venture funding to develop gene- and cell-therapy approaches, marking one of the largest life-sciences venture rounds and among Seattles biggest. SEC filings indicate total capital and non-cash assets may total about $866.8 million, though the company declined to disclose valuation.
People
-
Steve Harr Executive, Co-founder and CEO
